

Cardiovascular Spring 2018 Cycle

CSAC Review and Endorsement

October 23-24, 2018

Cardiovascular

- Cardiovascular disease (CVD) is the leading cause of death for men and women in the United States.
- CVD kills nearly one in four Americans and costs \$312 billion per year, more than 10 percent of annual health expenditures.¹
- Measures that assess clinical care performance and patient outcomes are critical to reducing the negative impacts of CVD.
- Cardiovascular portfolio of measures is one of the largest (e.g., primary prevention and screening, coronary artery disease (CAD), ischemic vascular disease (IVD), acute myocardial infarction (AMI), etc.)
- Gaps remain in patient-reported outcomes and patientcentric composite measures.

¹ Agency for Healthcare Research and Quality (AHRQ). 2015 National Healthcare Quality and Disparities Report and 5th Anniversary Update on the National Quality Strategy. Rockville, MD: AHRQ; 2016. http://www.ahrq.gov/research/findings/nhqrdr/nhqdr15/index.html. Last accessed March 2018.

Cardiovascular

- The Committee evaluated one measure undergoing maintenance review in the following topic area:
 - Percutaneous Coronary Intervention (PCI)
- One measure was submitted to the Scientific Methods Panel for review but was withdrawn prior to Committee evaluation:
 - 0273e Hybrid Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) following Acute Myocardial Infarction (AMI)

Cardiovascular Standing Committee Recommendations

- The Committee recommended the one maintenance measure for endorsement:
 - 0535 30-Day All-Cause Risk-Standardized Mortality Rate following Percutaneous Coronary Intervention (PCI) for Patients without ST Segment Elevation Myocardial Infarction (STEMI) and without Cardiogenic Shock

Measure Evaluation Summary

	Maintenance Measures	New Measures	TOTAL Measures
Submitted	2	0	2
Measures Recommended	1	0	1
Measures Not Recommended	0	0	0
Measures Withdrawn from Consideration	1	0	1
Reasons for not recommending:	Importance – 0 Scientific Acceptability – 0 Overall – 0	Importance – 0 Scientific Acceptability – 0 Overall – 0	

Public and NQF Member Comments Received/Member Expression of Support

- NQF received one comment from one member organization.
- The post-evaluation comment supported recommending measure #0535 for endorsement.
- No NQF members expressed their support.

Timeline and Next Steps

Process Step	Timeline	
Appeals Period	October 26, 2018-November 26, 2018	
Adjudication of Appeals	November 27, 2018-December 21, 2018	
Final Report	Early February 2019	



Project webpage: <u>http://www.qualityforum.org/Project_Pages/Cardiovascular.aspx</u>

Project email address: cardiovascular@qualityforum.org